PATENT, TRADEMARK AND LICENSE MORTGAGE
--------------------------------------
THIS PATENT, TRADEMARK AND LICENSE MORTGAGE (the "Mortgage") made as of
this 31st day of December, 1998 by FOUNTAIN PHARMACEUTICALS, INC., a Delaware
corporation, having its principal place of business at 0000 Xxxxx Xxxxx Xxxx,
Xxxxx, Xxxxxxx 00000 ("Mortgagor"), in favor of XXXXXX X. XXXXXXXXX, an
individual, with an office at 0000 Xxxxxxxxx Xxxxx, Xxxxx 000, Xxxxxxxx, Xxxxxxx
00000 ("Mortgagee"):
W I T N E S S E T H:
--------------------
WHEREAS, Mortgagor and Mortgagee are parties to a certain Credit and
Security Agreement, dated as of December 31,1998 ("the Security Agreement"), and
the related Secured Promissory Note (the "Note") and other related loan
documents of even date herewith (collectively, the "Security Documents"), which
Security Documents provide (i) for Mortgagee to, from time to time, extend
credit to or for the account of Mortgagor and (ii) for the grant by Mortgagor to
Mortgagee of a security interest in certain of Mortgagor's assets, including,
without limitation, its patents, patent applications, trademarks, trademark
applications, tradenames, service marks, service xxxx applications, goodwill and
licenses;
NOW, THEREFORE, in consideration of the premises set forth herein and
for other good and valuable consideration, the receipt, sufficiency and adequacy
of which are hereby acknowledged, Mortgagor agrees as follows:
1. Capitalized Terms. All terms capitalized but not otherwise defined
herein shall have the same meanings herein as in the Security Agreement.
2. Mortgage of Patents, Trademarks and Licenses. To secure the complete
and timely satisfaction of all of Mortgagor's "Obligations" (as defined in the
Security Agreement), Mortgagor hereby grants, bargains, assigns, mortgages,
pledges, sells, creates a security interest in, transfers, and conveys to
Mortgagee, as and by way of a first mortgage and security interest having
priority over all other security interests, with power of sale, to the extent
permitted by law or by the specific license agreements, upon the occurrence of
an Even of Default (as defined in the Security Agreement) all of Mortgagor's
right, title and interest in and to all of its now existing and hereafter
created or acquired:
1
(i) patents and patent applications, including, without
limitation, the inventions and improvements described and claimed
therein, and those patents listed on Exhibit A attached hereto and
hereby made a part hereof, and (a) the reissues, divisions,
continuations, renewals, extensions and continuations-in-part thereof,
(b) all income, damages and payments now and hereafter due or payable
under or with respect thereto, including, without limitation, damages
and payments for past or future infringements thereof, (c) the right to
xxx for past, present and future infringements thereof, and (d) all
rights corresponding thereto throughout the world (all of the foregoing
patents and applications, together with the items described in clauses
(a)-(d) of this subsection 2(i), are sometimes hereinafter to
individually as a "Patent" and, collectively, as the "Patents");
(ii) trademarks, trademark registrations, trademark
applications, tradenames and tradestyles, service marks, service xxxx
registrations and service xxxx applications, including, without
limitation, the trademarks, tradenames, service marks and applications
and registrations thereof listed on Exhibit B attached hereto and
hereby made a part hereof, and (a) renewals or extensions thereof, (b)
all income, damages and payments now and hereafter due or payable with
respect thereto, including, without limitation, damages and payments
for past or future infringements thereof, (c) the right to xxx for
past, present and future infringements thereof, and (d) all rights
corresponding thereto throughout the world (all of the foregoing
trademarks, tradenames and tradestyles, service marks and applications
and registrations thereof, together with the items described in clauses
(a)-(d) of this subsection (ii), are sometimes hereinafter referred
individually as a "Trademark," and, collectively, as the "Trademarks");
(iii) all license agreements with respect to any of the
Patents or the Trademarks or any other patent, trademark, service xxxx
or any application or registration thereof or any other tradename or
tradestyle between Mortgagor and any other party, whether Mortgagor is
a licensor or licensee under any such license agreement, including,
without limitation, the licenses listed on Exhibit C attached hereto
and hereby made a part hereof (all of the foregoing license agreements
and Mortgagor's rights thereunder are referred to collectively as the
"Licenses"); and
(iv) the goodwill of Mortgagor's business connected with and
symbolized by the Trademarks.
3. Warranties and Representations. Mortgagor warrants and represents to
Mortgagee that:
(i) Each of the Patents, Trademarks and Licenses is valid and
enforceable;
(ii) Mortgagor is the sole and exclusive owner of the entire
and unencumbered right, title and interest in and to each of the
Patents, Trademarks and Licenses, free and clear of any liens, charges
and encumbrances, including, without limitation, licenses, shop rights
and covenants by Mortgagor not to xxx third persons;
2
(iii) Mortgagor has no notice of any suits or actions
commenced or threatened with reference to the Patents, Trademarks or
Licenses; and
(iv) Mortgagor has the right to execute and deliver this
Mortgage and perform its terms and has entered into or will enter into
written agreements with each of its present and future employees,
agents and consultants which will enable it to comply with the
covenants contained herein.
4. Restrictions on Future Agreements. Mortgagor agrees that until the
Obligations shall have been satisfied in full and the Security Documents shall
have been terminated, Mortgagor shall not sell or assign its interest in, or
grant any license under, the Patents, Trademarks or Licenses, or enter into any
other agreement with respect to the Patents, Trademarks or Licenses which is
inconsistent with Mortgagor's obligations under this Mortgage, without the prior
written consent of Mortgagee, and Mortgagor further agrees that it shall not
take any action, or permit any action to be taken by others subject to its
control, including licensees, or fail to take any action (solely with respect to
the Patents and the Tradenames), which would affect the validity or enforcement
of the rights transferred to Mortgagee under this Mortgage.
5. New Patents, Trademarks, and Licenses. Mortgagor represents and
warrants that the Patents, Trademarks and Licenses listed on Exhibits A, B and
C, respectively, constitute all of the Patents, Trademarks, and Licenses now
owned by Mortgagor. All other patent rights or investments of Mortgagor shall be
subject to this Mortgage.
6. Royalties; Terms. The term of the mortgages granted herein shall
extend until the earlier of (i) the expiration of each of the respective
Patents, Trademarks and Licenses assigned hereunder, and (ii) the Obligations
have been paid in full and the Security Documents have been terminated. Upon the
occurrence of an Event of Default, Mortgagor agrees that the use by Mortgagee of
all Patents, Trademarks and Licenses shall be worldwide and without any
liability for royalties or other related charges from Mortgagee to the
Mortgagor.
7. Grant of License to Mortgagor. Unless and until an Event of Default
shall have occurred, Mortgagee hereby grants to Mortgagor the exclusive,
nontransferable right and license to use the Trademarks in the ordinary course
of its business, to exercise Mortgagee's rights under the Licenses, and to make,
have made, use and sell the inventions disclosed and claimed in the Patents for
Mortgagor's own benefit and account and for none other. Mortgagor shall use the
Trademarks only on goods of at least as high quality as the goods on which
Mortgagor or its predecessor used the goods prior to the date hereof. Mortgagor
agrees not to sell or assign its interest in, or grant any sublicense under, the
license granted to Mortgagor in this Section 7, without the prior written
consent of Mortgagee. From and after the occurrence of an Event of Default,
Mortgagor's license with respect to the Patents, Trademarks and Licenses set
forth in this Section 7 shall terminate forthwith, and Mortgagee shall have, in
addition to all other rights and remedies given it by this Mortgage, those
allowed by law and the rights and remedies of a secured party under the Uniform
3
Commercial Code as enacted in any of the jurisdictions in which the Patents,
Trademarks or Licenses may be located, and shall have immediate power of sale
and full and unencumbered ownership of the Patents, Trademarks and Licenses.
8. Mortgagee's Right to Inspect. Mortgagee shall have the right, at any
time and from time to time during normal business hours and prior to payment in
full of the Obligations, to inspect Mortgagor's premises and to examine
Mortgagor's books, records and operations, including, without limitation,
Mortgagor's quality control processes. Upon the occurrence of an Event of
Default, Mortgagor agrees that Mortgagee, or a conservator appointed by
Mortgagee, shall have the right to establish such additional product quality
controls as Mortgagee, or said conservator, in its sole judgment, may deem
necessary to assure maintenance of the quality of products sold by Mortgagor
under the Trademarks.
9. Release of Mortgage. This Mortgage is made for collateral purposes
only. Upon, but only upon, payment in full of the Obligations and termination of
the Security Documents, Mortgagee shall execute and deliver to Mortgagor all
deeds, assignments and other instruments, and shall take such other actions, as
may be necessary or proper to re-vest in Mortgagor full title to the Patents,
Trademarks, and Licenses, subject to any disposition thereof which may have been
made by Mortgagee pursuant hereto or pursuant to the Security Documents.
10. Expenses. All reasonable expenses incurred in connection with the
performance of any of the agreements set forth herein shall be borne by
Mortgagor. All reasonable fees, costs and expenses, of whatever kind or nature,
including reasonable attorneys' and paralegals' fees and legal expenses,
incurred by Mortgagee in connection with the filing or recording of any
documents (including, without limitation, all taxes in connection therewith) in
public offices, the payment or discharge of any taxes, counsel fees, maintenance
fees, encumbrances or otherwise in protecting, maintaining or preserving the
Patents, Trademarks and Licenses, or in defending or prosecuting any actions or
proceedings arising out of or related to the Patents, Trademarks and Licenses,
shall be borne by and paid by Mortgagor on demand by Mortgagee and until so paid
shall be added to the principal amount of Mortgagor's Obligations and shall bear
interest at the rate set forth in the Note.
11. Duties of Mortgagor. Mortgagor shall have the duty (i) to prosecute
diligently any material patent, trademark or service xxxx applications pending
as of the date hereof or thereafter until the Obligations shall have been paid
in full, (ii) to make application on unpatented but patentable inventions and on
trademarks and service marks, as appropriate, and to the extent commercially
reasonable, (iii) to preserve and maintain all rights in the Patents, Trademarks
and Licenses, and (iv) to ensure that the Patents, Trademarks and Licenses are
and remain enforceable. Any expenses incurred in connection with Mortgagor's
obligations under this Section 11 shall be borne by Mortgagor. Mortgagor shall
not abandon any right to file a patent, trademark or service xxxx application,
or abandon any pending patent application, or any other Patent, Trademark or
License without the consent of Mortgagee, except as may be commercially
reasonable.
4
12. Mortgagee's Right to Xxx. After the occurrence of an Event of
Default, Mortgagee shall have the right, but shall in no way be obligated, to
bring suit in its own name to enforce the Patents, Trademarks and Licenses, and,
if Mortgagee shall commence any such suit, Mortgagor shall, at the request of
Mortgagee, do any and all lawful acts and execute any and all proper documents
required by Mortgagee in aid of such enforcement and Mortgagor shall promptly,
upon demand, reimburse and indemnify Mortgagee for all reasonable costs and
expenses incurred by Mortgagee in the exercise of its rights under this Section
12.
13. Waivers. No course of dealing between Mortgagor and Mortgagee, nor
any failure to exercise, nor any delay in exercising, on the part of Mortgagee,
any right, power or privilege hereunder or under the Security Documents shall
operate as a waiver thereof.
14. Severability. The provisions of this Mortgage are severable, and if
any clause or provision shall be held invalid and unenforceable in whole or in
part in any jurisdiction, then such invalidity or unenforceability shall affect
only such clause or provision, or part thereof, in such jurisdiction.
15. Modification. This Mortgage cannot be altered, amended or modified
in any way, except as specifically provided in Section 5 hereof or by a writing
signed by the parties hereto.
16. Cumulative Remedies; Power of Attorney; Effect on Financing
Agreement. All of Mortgagee's rights and remedies with respect to the Patents,
Trademarks and Licenses, whether established hereby or by the Security
Documents, or by any other agreements or by law shall be cumulative and may be
exercised singularly or concurrently. Upon the occurrence of an Event of
Default, Mortgagor hereby authorizes Mortgagee to make, constitute and appoint
any officer or agent of Mortgagee as Mortgagee may select, in its sole
discretion, as Mortgagor's true and lawful attorney-in-fact, with power to (i)
endorse Mortgagor's name on all documents necessary or desirable for Mortgagee
in the use of the Patents, Trademarks and Licenses, or (ii) take any other
actions with respect to the Patents, Trademarks and Licenses as Mortgagee deems
to be in the best interest of Mortgagee, or (iii) grant or issue any license
under the Patents, Trademarks or Licenses to anyone, or (iv) subject to
applicable law, assign, pledge, convey or otherwise transfer title in or dispose
of the Patents, Trademarks or Licenses to anyone. Mortgagee hereby ratifies all
that such attorney shall lawfully do or cause to be done by virtue hereof. This
power of attorney shall be irrevocable until the Obligations shall have been
paid in full. Mortgagee shall have, in addition to all other rights and remedies
given it by the terms of this Mortgage and the Security Documents, all rights
and remedies allowed by law and the rights and remedies of a secured party under
the Uniform Commercial Code as enacted in any jurisdiction in which the Patents,
Trademarks or Licenses may be located.
17. Binding Effect; Benefits. This Mortgage shall be binding upon the
Mortgagor and its respective successors and assigns, and shall inure to the
benefit of Mortgagee, its successors, nominees and assigns.
5
18. Governing Law. This Mortgage shall be governed by and construed in
accordance with the internal laws of the State of Wyoming.
19. Further Assistance. Mortgagor and Mortgagee agree to execute and
deliver such further agreements, instruments and documents, and to perform such
further acts, as either party shall reasonably request from time to time in
order to carry out the purpose of this Mortgage and the agreements set forth
herein.
20. Survival of Representations. All representations and warranties
contained in this Mortgage shall survive the execution and delivery of this
Mortgage and shall be remade on the date of each borrowing under the Note.
IN WITNESS WHEREOF, following approval by all of its directors,
Fountain Pharmaceuticals, Inc. has duly executed this Mortgage in favor of
Xxxxxx X. Xxxxxxxxx as of the date first written above.
ATTEST: FOUNTAIN PHARMACEUTICALS, INC.
______________________________ By: /s/ Xxxxxx X. Xxxxxxx
------------------------------
Title: Corporation Secretary of Title: President/CEO
Fountain Pharmaceuticals, Inc.
AGREED AND ACCEPTED to this
31st day of December, 1998
/s/ Xxxxxx X. Xxxxxxxxx
-------------------------------
Xxxxxx X. Xxxxxxxxx
6
THIS INSTRUMENT PREPARED BY AND
AFTER FILING RETURN TO:
Xxxxxx X. Xxxxxxxxx III, Esq.
Xxxxxxx X. Xxxxxx, Esq.
Eaglestone Capital Services, Inc.
000 Xxxxxxxxx, Xxxxx 0000
Xxxx Xxxxx, Xxxxxxxxxx 00000
STATE OF FLORIDA )
) ss.
COUNTY OF Pinellas )
The foregoing Patent, Trademark and License Mortgage was
executed and acknowledged before me this 6th day of January, 1999, by Xxxxxx X.
Xxxxxxx and ______________________, personally known to me to be the
President/CEO and _______________________, respectively, of Fountain
Pharmaceuticals, Inc., a Delaware corporation, on behalf of such corporation.
/s/ Xxxxxxx X. Xxxxxx
---------------------------
Notary Public No. CC520799
Pinellas County, Florida
My commission expires:
December 25, 1999
-----------------
7
FOUNTAIN PHARMACEUTICALS, INC.
INTELLECTUAL PROPERTY - Domestic and Foreign
January 12, 1999
------------------------------------------------------------------------------------------------------------------------------------
S&A File No. Country Serial No. Filing Date Patent No. Issue Date Status
------------ ------- ---------- ----------- ---------- ---------- ------
------------------------------------------------------------------------------------------------------------------------------------
10767/0800 SERIES: METHOD FOR MAKING SOLVENT DILUTION MICROCARRIERS
This series of patents claims technology associated with adding the
active ingredient at the time of manufacture.
Specifically, this series of patents covers (1) methods, consisting
essentially of four steps, for forming solvent dilution microcarrier
vehicles (SDMCs) in which the active ingredient is added in the initial
preparation step, (2) SDMCs made according to the claimed method, and
(3) an optically clear solution made by following the first three
preparation steps. The method consists of the following steps: (1)
mixing the active ingredient with a bilayer-forming material in a
nonaqueous solvent; (2) adding water to form a turbid solution; (3)
adding a nonaqueous solvent to form an optically clear solution; and
(4) an organization step, which is either an aerosolization step, an
additional dilution step, or a drying/rehydrating step.
------------------------------------------------------------------------------------------------------------------------------------
X-00000 X.X. 000000 06/08/88 ABANDONED - Appeal Withdrawn
(10767/00801)
------------------------------------------------------------------------------------------------------------------------------------
B-26623CN CANADA 602057 06/07/89 PENDING - Taxes due
(10767/00819) after grant
Issue Fee paid 08/03/98
------------------------------------------------------------------------------------------------------------------------------------
B-26623IS ISRAEL 90561 06/07/89 90561 11/19/93 Expires 06/07/09
(10767/00821) Taxes due 07/07/99; 03; 07
------------------------------------------------------------------------------------------------------------------------------------
X-00000XX XXXXX 8902007 06/08/89 2013531 03/30/90 Expires 06/08/09
(10767/00822) Taxes due 06/08/94 and
yearly thereafter until expiration
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP U.S. 07/460838 06/08/89 5133965 07/28/92 Expires 07/28/09
(10767/00802) Maintenance Fees
due 01/28/00; 04
------------------------------------------------------------------------------------------------------------------------------------
Page 1 of 6
------------------------------------------------------------------------------------------------------------------------------------
S&A File No. Country Serial No. Filing Date Patent No. Issue Date Status
------------ ------- ---------- ----------- ---------- ---------- ------
------------------------------------------------------------------------------------------------------------------------------------
X-00000XXX/XX XXXXXXXXX 37777/89 06/08/89 628355 01/22/93 Expires 06/08/09
(10767/00803) Taxes due 06/08/94 and
yearly thereafter until expiration
------------------------------------------------------------------------------------------------------------------------------------
X-00000XXXX/XX XXXXXXXXX 27194/92 10/20/92 ABANDONED
(10767/00807) (Divisional of 12/08/94
Australian Serial No.
37777/89)
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP/BZ BRAZIL PCT/US89/ 06/08/89 ABANDONED
(10767/00804) 02454
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP/EP EUROPEAN PATENT 89907512.1 06/08/89 0372070 01/15/97 Expires 06/08/09
(10767/00809) CONVENTION
------------------------------------------------------------------------------------------------------------------------------------
10767/00823 AUSTRIA 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
10767/00827 BELGIUM 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
10767/00824 FRANCE 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
10767/00825 GREAT BRITAIN 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
10767/00811 GERMANY 0372070 06/08/89 68927669908 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
10767/00831 HONG KONG 981067494 06/25/98 PENDING
------------------------------------------------------------------------------------------------------------------------------------
Page 2 of 6
------------------------------------------------------------------------------------------------------------------------------------
S&A File No. Country Serial No. Filing Date Patent No. Issue Date Status
------------ ------- ---------- ----------- ---------- ---------- ------
------------------------------------------------------------------------------------------------------------------------------------
00000/00000 XXXXX 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
10767/00828 LUXEMBOURG 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
10767/00829 NETHERLANDS 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
00000/000 XXXXXX 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
Expires 06/08/09
------------------------------------------------------------------------------------------------------------------------------------
SWITZERLAND 0372070 06/08/89 0372070 01/15/97 Annual Taxes Due June 8
(Liechtenstein) Expires 06/08/09
10767/00817
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP/JA JAPAN 506883/89 06/08/89 PENDING - Taxes due after grant
(10767/00812) Response to Office Action due 09/02/98
(extendable)
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP/KR SOUTH KOREA 90/700244 02/07/90 ABANDONED
(10767/00813) 06/07/94
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP/NR NORWAY 900591 06/08/89 180771 06/18/97 Expires 06/08/09
(10767/00814) Taxes due 06/08/94 and
yearly thereafter until expiration
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP/SI SINGAPORE 96095336 06/08/89 PENDING
(10767/00816) Grant Fee due 10/03/99
Published
------------------------------------------------------------------------------------------------------------------------------------
Page 3 of 6
------------------------------------------------------------------------------------------------------------------------------------
S&A File No. Country Serial No. Filing Date Patent No. Issue Date Status
------------ ------- ---------- ----------- ---------- ---------- ------
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIP/PCT PARIS COOPERATION TREATY PCT/US89/ 06/08/89 FILE CLOSED -
(10767/00815) 02454 Entered National Stage
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIPC U.S. 07/882801 05/14/92 5269979 12/14/93 Expires 12/14/10
(10767/00805) Maintenance Fees
due 06/14/01; 05
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIPD1 U.S. 07/885462 05/19/92 ABANDONED in favor of Divisional
(10767/00806) Application
------------------------------------------------------------------------------------------------------------------------------------
B-26623CIPDC U.S. 08/122808 09/17/93 ABANDONED 07/14/94
(10767/00808)
------------------------------------------------------------------------------------------------------------------------------------
10767/00900 SERIES: LIPOSOME PREPARATION AND ITS USE FOR TREATMENT OF BURN WOUNDS
------------------------------------------------------------------------------------------------------------------------------------
B-33694 U.S. 08/027138 03/05/93 ABANDONED 11/22/94
(10767/00901)
------------------------------------------------------------------------------------------------------------------------------------
10767/01001 SERIES: VACCINE DELIVERY SYSTEM
This patent series focuses on precursor solutions and the so-called
Aremote-loadable@ technology, where a precursor solution is first made
and an active ingredient added at a Aremote@ point in time. For
example, in this case the product may be a precursor solution to which
another manufacturer adds desired active ingredients to form SDMC=s.
Specifically, this patent series covers (1) method, consisting
essentially of four preparation steps, for forming solvent dilution
microcarriers (SDMCs) in which the active ingredient is added in the
last preparation step and (2) a shelf stable, optically clear precursor
solution made according to the first three preparation steps. The
method consists of the following steps: (1) mixing the bilayer forming
material in a nonaqueous solvent; (2) adding water to form a turbid
solution; (3) adding a nonaqueous solvent to form a shelf stable
optically clear precursor solution; and (4) adding the active
ingredient to the optically clear precursor solution. The active
ingredient can be added either immediately or remotely to the optically
clear precursor solution.
Page 4 of 6
------------------------------------------------------------------------------------------------------------------------------------
S&A File No. Country Serial No. Filing Date Patent No. Issue Date Status
------------ ------- ---------- ----------- ---------- ---------- ------
------------------------------------------------------------------------------------------------------------------------------------
B-33910 U.S. 08/023971 02/26/93 ABANDONED 11/14/94
(10767/01001)
------------------------------------------------------------------------------------------------------------------------------------
B-33910CIP U.S. 08/507401 01/02/96 PENDING
(10767/01002) Notice of Allowance dated 09/02/98
received
------------------------------------------------------------------------------------------------------------------------------------
B-33910CIP/PCT PARIS COOPERATION TREATY PCT/US94/ 02/25/94 FILE CLOSED--
(10767/01008) 02053 Entered National Stage
------------------------------------------------------------------------------------------------------------------------------------
X-00000XXX/XX XXXXXXXXX 6250694 02/25/94 677826 08/29/97 Expires 02/25/14
(10767/01003) Taxes due 02/25/97 and yearly
thereafter until expiration
------------------------------------------------------------------------------------------------------------------------------------
B-33910CIP/CN CANADA 2157125 02/25/94 PENDING - Request for
(10767/01004) Examination due 02/25/01
Taxes due 02/25/96 and yearly
thereafter until expiration
------------------------------------------------------------------------------------------------------------------------------------
B-33910CIP/EP EUROPEAN PATENT 94909807.3 02/25/94 PENDING - Taxes due 02/25/96 and yearly
(10767/01005) CONVENTION designating: thereafter until expiration
Austria, Belgium, Published Deadline to record in Hong
Denmark, France, Great Kong: 12/27/98
Britain, Germany,
Italy, Netherlands,
Portugal, Singapore,
Spain, Sweden, and
Switzerland/
(Liechtenstein)
------------------------------------------------------------------------------------------------------------------------------------
B-33910CIP/JA JAPAN 00000000 02/25/94 PENDING - Request for Examination due
(10767/01007) 02/25/01
------------------------------------------------------------------------------------------------------------------------------------
Page 5 of 6
------------------------------------------------------------------------------------------------------------------------------------
S&A File No. Country Serial No. Filing Date Patent No. Issue Date Status
------------ ------- ---------- ----------- ---------- ---------- ------
------------------------------------------------------------------------------------------------------------------------------------
B-33910CIP/SI SINGAPORE 96092499 02/25/94 PENDING - Request for Examination
(10767/1009) filed
Published
------------------------------------------------------------------------------------------------------------------------------------
B-34347 U.S. 08/069267 05/28/93 ABANDONED 01/20/95
(10767/01101)
------------------------------------------------------------------------------------------------------------------------------------
Page 6 of 0
XXXXXXX X
Xxxxxxxxxx
Xxxxxx Xxxxxx Trademarks and Trademark Registrations:
-----------------------------------------------------
Trademark Reg. No. Goods
--------- -------- -----
LYPHAZOME
OCTAZOME in Block Letter Form 1,714,885
OCTAZOME & Design 1,799,024
"FP" in Stylized Form 1,810,369
DAYLONG 1,811,787
1,822,214
State Trademarks and Trademark Registrations:
---------------------------------------------
State Trademark Reg. No. Goods
----- --------- -------- -----
Foreign Trademarks and Trademark Registrations:
-----------------------------------------------
Tradenames: Reg. No.
----------- --------
Trademark Applications:
-----------------------
Trademark Application No. Application Date: Country
--------- --------------- ----------------- -------
OCTAZOME EXCELL 75/568819 10/13/98 United States
BOTANICAL BODY DRENCH 75/568822 10/13/98 United Xxxxxx
XXXX XXXXXX 00/000000 00/00/00 Xxxxxx Xxxxxx
EXHIBIT C
Licenses
--------
See Schedule 4(p)(ii) Contracts in Disclosure Schedules to Stock Purchase and
Subscription Agreement between Fountain Pharmaceuticals, Inc. and Fountain
Holdings, LLC dated July 11, 1997.
